Mani T. Valarmathi

Religen Inc. | A Life Science Company

Mani T. Valarmathi is currently Director of Research and Development at Religen Inc., a Life Science Company in Pennsylvania, USA. He began his scientific career as a cancer geneticist, but soon became captivated with the emerging and translational fields of stem cell biology, tissue engineering, and regenerative medicine. After obtaining a bachelor’s degree in Chemistry from the University of Madras, Chennai, Tamil Nadu, India, he obtained an MBBS in Medicine and Surgery and MD in Pathology from the same university, as well as a Ph.D. in Medical Biotechnology from All-India Institute of Medical Sciences, New Delhi, India. Over the past two decades, he has had extensive experience in research on various types of stem cells, and his research work has been focused on creating bioengineered human 3D vascularized tissues constructs for implantation purposes. At present, much of his research is directed towards developing innovative molecular genetic testing for precision and genetic medicine. He is a member of many prestigious national and international professional societies and scientific organizations, including the International Society for Stem Cell Research (ISSCR), Tissue Engineering and Regenerative Medicine International Society (TERMIS), American Association for Cancer Research (AACR), American Society for Investigative Pathology (ASIP), American Society for Clinical Pathology (ASCP), American Chemical Society (ACS), European Society of Cardiology (ESC), International Society for Heart Research (ISHR), American Society of Gene & Cell Therapy (ASGCT), and American Heart Association (AHA).

3books edited

3chapters authored

Latest work with IntechOpen by Mani T. Valarmathi

A rare disease is any disease or condition that affects a small percentage of the population. Many rare conditions are life-threatening or chronically debilitating, and unfortunately do not have appropriate treatments, rendering them incurable. In recent years, there has been substantial development in the area of rare disease research and its clinical applications, for instance, rare disease biology and genomics, epidemiology and preventions, early detection and screening, and diagnosis and treatment. In this context, this book consolidates the recent advances in rare disease biology and therapeutics, covering a wide spectrum of interrelated topics, and disseminates this essential knowledge in a comprehensible way to a greater scientific and clinical audience as well as patients, caregivers, and drug and device manufacturers, especially to support rare disease product development. Chapters cover such diseases as Felty’s syndrome, Löfgren’s syndrome, mesothelioma, epidermolysis bullosa, and more. This book is a valuable resource not only for medical and allied health students but also for researchers, clinical and nurse geneticists, genetic counselors, and physician assistants.

Go to the book